Research Site

Mineola, New York 11501

2 studies enrolling now · 48 studies all time

What they study most

Advanced Breast Cancer, Advanced Solid Tumours, Advanced Upper Gastrointestinal Tract Adenocarcinoma, Anemia, Anemia in Chronic Kidney Disease Patients Not on Dialysis, Arthritis, Rheumatoid, Asthma, Atherothrombosis, Biliary Tract Cancer, COVID-19, Carcinoma, Carcinoma Non-small Cell Lung

Studies at this site

• Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer — Recruiting now
• Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) — Recruiting now
• Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) — Running, not enrolling
• A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body — Running, not enrolling
• Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN) — Running, not enrolling
• Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) — Running, not enrolling
• AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 — Running, not enrolling
• To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. — Running, not enrolling
• First in Human Study of AZD9592 in Solid Tumors — Running, not enrolling
• A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features — Running, not enrolling
• AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. — Running, not enrolling
• Registry of Patients With Hypophosphatasia — Enrolling by invitation
• Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE) — Completed
• Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients — Completed
• Durvalumab Long-Term Safety and Efficacy Study — Completed
• A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer — Completed
• Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults — Completed
• Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment. — Completed
• A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children — Completed
• Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease — Completed
• Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments — Completed
• Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms — Stopped early
• Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD) — Completed
• Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction — Completed
• A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness — Completed
• Osteonecrosis of the Jaw (ONJ) Case Registry — Completed
• A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants. — Completed
• Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer — Completed
• Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet — Completed
• Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History — Completed
• Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes — Completed
• PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response — Completed
• Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis — Completed
• Evaluating a Novel Onco-genetic BRCA Testing Counselling Model Among Patients With Ovarian Cancer — Completed
• An Observational Study of Respiratory Syncytial Virus (RSV) Hospitalizations in Preterm Infants — Completed
• Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis — Completed
• A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone — Completed
• JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab — Completed
• AZD9291 US Expanded Access Program — NO_LONGER_AVAILABLE
• Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin — Completed
• Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis — Completed
• An Observational Study to Assess RSV-associated Illness in Adults With COPD and/or CHF — Completed
• AMG 151 Amgen Protocol Number 20100761 — Completed
• Iressa Expanded Access Program (EAP) — Completed
• An Observational Study to Assess Respiratory Syncytial Virus (RSV) Respiratory Events Among Premature Infants — Completed
• A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children — Completed
• A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients — Completed
• Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C) — Stopped early